share_log

Earnings Call Summary | Evogene(EVGN.US) Q4 2023 Earnings Conference

Futu News ·  Mar 8 03:33  · Conference Call

The following is a summary of the Evogene Ltd. (EVGN) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • Evogene reported a significant increase in revenue, moving from approximately $1.7 million in 2022 to $5.6 million in 2023.

  • The company showed a solid cash balance of approximately $31.1 million by the end of 2023 and expects additional cash injections through collaborations and product sales.

  • Operating loss and net loss for 2023 showed a slight dip compared to 2022– operating loss $26.5 million in 2023 from $26.9 million in 2022, and net loss $26 million in 2023 from $29.8 million in 2022.

  • Evogene expects a marked decline in cash usage in 2024, thanks to the anticipated increase in revenue and decrease in expenses.

  • The company raised around $8.5 million through a direct offering of shares to institutional investors in 2023.

Business Progress:

  • Evogene evolved strategic partnerships validating their AI tech engines, leading to collaborations with notable companies such as Bayer, Corteva, ICL, and Syngenta.

  • Subsidiaries made substantial contributions; AgPlenus achieved major milestones with Bayer and Corteva, and Lavie Bio made significant strides in distribution partnerships, while Biomica's flagship product, BMC128, showed promising results in Phase I clinical trials.

  • The Evogene Group expects to witness an increase in product sales, such as Casterra's elite castor varieties and Lavie's bio-inoculant Yalos.

  • The company secured new partnerships with seed producers in Africa and Brazil, which aids in diversification and strengthens the supply chain.

  • To accommodate for growth, Evogene is making additions to its employee base, including agronomy experts in castor cultivation and plans to set up a subsidiary in Kenya.

More details: Evogene IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment